http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA#Head
http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA#assertion
http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA#provenance
http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA#pubinfo
http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA#assertion
http://purl.obolibrary.org/obo/DOID_3908
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_3908
http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB09035
http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA#association
http://www.w3.org/2000/01/rdf-schema#label
opdivo is a programmed death receptor 1 pd 1 blocking antibody indicated for the treatment of 1 1 1 2 1 3 a 1 4 1 5 1 5 a 1 6 1 7 a 1 8 a 1 9 a 1 1 a opdivo as a single agent or in combination with ipilimumab is indicated for the treatment of patients with unresectable or metastatic melanoma opdivo is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection opdivo is indicated for the treatment of patients with metastatic non small cell lung cancer nsclc with progression on or after platinum based chemotherapy patients with egfr or alk genomic tumor aberrations should have disease progression on fda approved therapy for these aberrations prior to receiving opdivo opdivo is indicated for the treatment of patients with metastatic small cell lung cancer sclc with progression after platinum based chemotherapy and at least one other line of therapy this indication is approved under accelerated approval based on overall response rate and duration of response see clinical studies 14 4 opdivo in combination with ipilimumab is indicated for the treatment of patients with intermediate or poor risk previously untreated advanced rcc opdivo is indicated for the treatment of adult patients with classical hodgkin lymphoma chl that has relapsed or progressed after autologous hematopoietic stem cell transplantation hsct and brentuximab vedotin or 3 or more lines of systemic therapy that includes autologous hsct this indication is approved under accelerated approval based on overall response rate see clinical studies 14 6 opdivo is indicated for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck scchn with disease progression on or after platinum based therapy opdivo is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who this indication is approved under accelerated approval based on tumor response rate and duration of response see clinical studies 14 8 opdivo as a single agent or in combination with ipilimumab is indicated for the treatment of adult and pediatric patients 12 years and older with microsatellite instability high msi h or mismatch repair deficient dmmr metastatic colorectal cancer crc that has progressed following treatment with a fluoropyrimidine oxaliplatin and irinotecan this indication is approved under accelerated approval based on overall response rate and duration of response see clinical studies 14 9 opdivo is indicated for the treatment of patients with hepatocellular carcinoma hcc who have been previously treated with sorafenib this indication is approved under accelerated approval based on tumor response rate and durability of response see clinical studies 14 1
http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB09035
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA#provenance
http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA#pubinfo
http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA#sig
http://purl.org/nanopub/x/hasSignature
FH3USB3QOaerGJmhx4XzZ2b28e0UBIIXQ0gXfqpfTG3WyAA85sGaiH6DahAGZiyUXgSjpOw6u6UZNYcOBzfuxftlF1oTZ5Kyc+ZPHjGTO0him3fJoQU//DIVmZQ+Pw0BtaWIf3SETNcMJFM1FF5IrBIrhOdhi/LgQI2gwQQWTQw=
http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA
http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA
http://purl.org/dc/terms/created
2021-07-03T15:33:18.413+02:00
http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs